Clinical outcome after bone metastasis (BM) surgery in patients with differentiated thyroid carcinoma (DTC)

a retrospective study of 40 cases

Turrent Robert Nakayama, Keisuke Horiuchi, Michiro Susa, Itsuo Watanabe, Koota Watanabe, Takashi Tsuji, Morio Matsumoto, Yoshiaki Toyama, Hideo Morioka

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

OBJECTIVE: The purpose of this study is to identify factors that affect survival of patients with differentiated thyroid carcinoma with bone metastases and to optimize surgical treatment modality for bone metastatic lesion by comparing duration of patient survival and local control.

METHODS: We examined 52 bone metastatic lesions from 40 patients with differentiated thyroid carcinoma who were treated surgically between 1994 and 2008 at Keio University Hospital. Median follow-up time was 46 months (range: 4-233 months). Patients' disease-specific survival, local control duration and factors that potentially affected disease-specific survival after bone metastasis surgery were statistically analyzed.

RESULTS: The 2-, 5- and 10-year disease-specific survival rates were 77.2, 64.3 and 45.7%, respectively. Factors that were significantly associated with poor survival rates in multivariate analyses included age at bone metastasis surgery ≥65 years (P = 0.0068), time from diagnosis of primary cancer to bone metastasis surgery ≥5 years (P = 0.0018) and presence of visceral metastases (P = 0.0092). The 2-, 5- and 10-year local control rates in our series were 91.4, 72.7 and 63.6%, respectively. The 5-year local control rates for radical and palliative surgery were 84.4 and 55.3%, respectively, and differed significantly (P = 0.019).

CONCLUSIONS: Because disease-specific survival of patients with differentiated thyroid carcinoma is fairly good, inadequate treatment of bone metastatic lesions can result in severe disabilities. Therefore, radical surgery for bone metastatic lesions should be considered, especially for those with favorable prognostic factors.

Original languageEnglish
Pages (from-to)918-925
Number of pages8
JournalJapanese Journal of Clinical Oncology
Volume44
Issue number10
DOIs
Publication statusPublished - 2014 Oct 1

Fingerprint

Thyroid Neoplasms
Retrospective Studies
Neoplasm Metastasis
Bone and Bones
Survival
Survival Rate
Bone Neoplasms
Palliative Care
Multivariate Analysis
Therapeutics

Keywords

  • bone metastasis
  • differentiated thyroid carcinoma
  • prognosis
  • surgery
  • survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Clinical outcome after bone metastasis (BM) surgery in patients with differentiated thyroid carcinoma (DTC) : a retrospective study of 40 cases. / Nakayama, Turrent Robert; Horiuchi, Keisuke; Susa, Michiro; Watanabe, Itsuo; Watanabe, Koota; Tsuji, Takashi; Matsumoto, Morio; Toyama, Yoshiaki; Morioka, Hideo.

In: Japanese Journal of Clinical Oncology, Vol. 44, No. 10, 01.10.2014, p. 918-925.

Research output: Contribution to journalArticle

@article{2a99031e95cc4f9fa2e14fc715b11db0,
title = "Clinical outcome after bone metastasis (BM) surgery in patients with differentiated thyroid carcinoma (DTC): a retrospective study of 40 cases",
abstract = "OBJECTIVE: The purpose of this study is to identify factors that affect survival of patients with differentiated thyroid carcinoma with bone metastases and to optimize surgical treatment modality for bone metastatic lesion by comparing duration of patient survival and local control.METHODS: We examined 52 bone metastatic lesions from 40 patients with differentiated thyroid carcinoma who were treated surgically between 1994 and 2008 at Keio University Hospital. Median follow-up time was 46 months (range: 4-233 months). Patients' disease-specific survival, local control duration and factors that potentially affected disease-specific survival after bone metastasis surgery were statistically analyzed.RESULTS: The 2-, 5- and 10-year disease-specific survival rates were 77.2, 64.3 and 45.7{\%}, respectively. Factors that were significantly associated with poor survival rates in multivariate analyses included age at bone metastasis surgery ≥65 years (P = 0.0068), time from diagnosis of primary cancer to bone metastasis surgery ≥5 years (P = 0.0018) and presence of visceral metastases (P = 0.0092). The 2-, 5- and 10-year local control rates in our series were 91.4, 72.7 and 63.6{\%}, respectively. The 5-year local control rates for radical and palliative surgery were 84.4 and 55.3{\%}, respectively, and differed significantly (P = 0.019).CONCLUSIONS: Because disease-specific survival of patients with differentiated thyroid carcinoma is fairly good, inadequate treatment of bone metastatic lesions can result in severe disabilities. Therefore, radical surgery for bone metastatic lesions should be considered, especially for those with favorable prognostic factors.",
keywords = "bone metastasis, differentiated thyroid carcinoma, prognosis, surgery, survival",
author = "Nakayama, {Turrent Robert} and Keisuke Horiuchi and Michiro Susa and Itsuo Watanabe and Koota Watanabe and Takashi Tsuji and Morio Matsumoto and Yoshiaki Toyama and Hideo Morioka",
year = "2014",
month = "10",
day = "1",
doi = "10.1093/jjco/hyu099",
language = "English",
volume = "44",
pages = "918--925",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Clinical outcome after bone metastasis (BM) surgery in patients with differentiated thyroid carcinoma (DTC)

T2 - a retrospective study of 40 cases

AU - Nakayama, Turrent Robert

AU - Horiuchi, Keisuke

AU - Susa, Michiro

AU - Watanabe, Itsuo

AU - Watanabe, Koota

AU - Tsuji, Takashi

AU - Matsumoto, Morio

AU - Toyama, Yoshiaki

AU - Morioka, Hideo

PY - 2014/10/1

Y1 - 2014/10/1

N2 - OBJECTIVE: The purpose of this study is to identify factors that affect survival of patients with differentiated thyroid carcinoma with bone metastases and to optimize surgical treatment modality for bone metastatic lesion by comparing duration of patient survival and local control.METHODS: We examined 52 bone metastatic lesions from 40 patients with differentiated thyroid carcinoma who were treated surgically between 1994 and 2008 at Keio University Hospital. Median follow-up time was 46 months (range: 4-233 months). Patients' disease-specific survival, local control duration and factors that potentially affected disease-specific survival after bone metastasis surgery were statistically analyzed.RESULTS: The 2-, 5- and 10-year disease-specific survival rates were 77.2, 64.3 and 45.7%, respectively. Factors that were significantly associated with poor survival rates in multivariate analyses included age at bone metastasis surgery ≥65 years (P = 0.0068), time from diagnosis of primary cancer to bone metastasis surgery ≥5 years (P = 0.0018) and presence of visceral metastases (P = 0.0092). The 2-, 5- and 10-year local control rates in our series were 91.4, 72.7 and 63.6%, respectively. The 5-year local control rates for radical and palliative surgery were 84.4 and 55.3%, respectively, and differed significantly (P = 0.019).CONCLUSIONS: Because disease-specific survival of patients with differentiated thyroid carcinoma is fairly good, inadequate treatment of bone metastatic lesions can result in severe disabilities. Therefore, radical surgery for bone metastatic lesions should be considered, especially for those with favorable prognostic factors.

AB - OBJECTIVE: The purpose of this study is to identify factors that affect survival of patients with differentiated thyroid carcinoma with bone metastases and to optimize surgical treatment modality for bone metastatic lesion by comparing duration of patient survival and local control.METHODS: We examined 52 bone metastatic lesions from 40 patients with differentiated thyroid carcinoma who were treated surgically between 1994 and 2008 at Keio University Hospital. Median follow-up time was 46 months (range: 4-233 months). Patients' disease-specific survival, local control duration and factors that potentially affected disease-specific survival after bone metastasis surgery were statistically analyzed.RESULTS: The 2-, 5- and 10-year disease-specific survival rates were 77.2, 64.3 and 45.7%, respectively. Factors that were significantly associated with poor survival rates in multivariate analyses included age at bone metastasis surgery ≥65 years (P = 0.0068), time from diagnosis of primary cancer to bone metastasis surgery ≥5 years (P = 0.0018) and presence of visceral metastases (P = 0.0092). The 2-, 5- and 10-year local control rates in our series were 91.4, 72.7 and 63.6%, respectively. The 5-year local control rates for radical and palliative surgery were 84.4 and 55.3%, respectively, and differed significantly (P = 0.019).CONCLUSIONS: Because disease-specific survival of patients with differentiated thyroid carcinoma is fairly good, inadequate treatment of bone metastatic lesions can result in severe disabilities. Therefore, radical surgery for bone metastatic lesions should be considered, especially for those with favorable prognostic factors.

KW - bone metastasis

KW - differentiated thyroid carcinoma

KW - prognosis

KW - surgery

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=84922395223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922395223&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyu099

DO - 10.1093/jjco/hyu099

M3 - Article

VL - 44

SP - 918

EP - 925

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 10

ER -